Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel; perdida de inmunidad con el tiempo… de las vacunas
ECDC. Interim public health considerations for the provision of additional COVID-19 vaccine doses. Technical report, 1 September 2021.
Initial studies have shown that an additional COVID-19 vaccine dose in immunocompromised individuals enhances antibody response. Several studies thus far have looked at seropositive responses with a third mRNA COVID-19 vaccine dose in immunosuppressed people. Among immunocompromised individuals who had no detectable antibody response following a full COVID-19 vaccination course, 33-50% developed an antibody response to an additional third dose [83-87].
Disponible en:
y
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
estudio hecho con Pfizer–BioNTechDucloux D, Colladant M, Chabannes M, Yannaraki M, Courivaud C. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis. Kidney Int [Preprint]. 2021. DOI: 10.1016/j.kint.2021.06.025. Available at: https://www.sciencedirect.com/science/article/pii/S0085253821006554
3 doses of BNT162b2 (Pfizer–BioNTech)
Espi M, Charmetant X, Barba T, Pelletier C, Koppe L, Chalencon E, et al. Justification, safety, and efficacy of a third dose of mRNA vaccine in maintenance hemodialysis patients: a prospective observational study. medRxiv [Preprint]. 2021. DOI: 10.1101/2021.07.02.21259913. Available at: https://www.medrxiv.org/content/10.1101/2021.07.02.21259913v1
BNT162b2, and the safety and impact on immune responses of a 3rd dose (3D).
Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. N Engl J Med. 2021;385(7):661-2. Available at: https://www.nejm.org/doi/10.1056/NEJMc2108861
three doses of the messenger RNA vaccine BNT162b2 (Pfizer–BioNTech).
Longlune N, Nogier MB, Miedouge M, Gabilan C, Cartou C, Seigneuric B, et al. High immunogenicity of a messenger RNA based vaccine against SARS-CoV-2 in chronic dialysis patients. Nephrol Dial Transplant [Preprint]. 2021. DOI: 10.1093/ndt/gfab193. Available at: https://www.ncbi.nlm.nih.gov/pubmed/34057463
three doses of the messenger RNA vaccine BNT162b2 (Pfizer–BioNTech).
Werbel WA, Boyarsky BJ, Ou MT, Massie AB, Tobian AAR, Garonzik-Wang JM, et al. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series. Ann Intern Med. 2021 Available at: https://www.acpjournals.org/doi/full/10.7326/L21-0282
combinacion de vacunas RNA-jansen-etc.
Recomendaciones de administración de dosis de recuerdo frente a COVID-19
Aprobado por la Comisión de Salud Pública, el 23 de noviembre de 2021
En ellas recomienda dosis recuerdo vacunas de ARNm (0,3 ml de Comirnaty o 0,25 ml de Spikevax independientemente de la vacuna utilizada en la primovacunación.no he encontrado ningun paper que avale o refute esta decisión. Esta reciente publicacion mezcla diferentes vacunas con buenos resultados de inmunogenicidad t efectos secundarios.
- Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford–AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer–BioNtech, hearafter referred to as BNT).
No hay comentarios:
Publicar un comentario
Danos tu opinion, enriquece el post.